Basic Zydena Information

• INN (International Nonproprietary Name): Udenafil
• Brand Names Available In Australia: Zydena; Zidena; Udenafilo — no TGA approval or branded packaging reported for the U.S., Canada or EU as of July 2025
• ATC Code: G04BE10
• Forms & Dosages: Tablet; strengths 100 mg and 200 mg; typical blister sizes 4, 8 or 10 tablets (100 mg) and 4 or 8 tablets (200 mg); markets include Korea, CIS and parts of Asia
• Manufacturers In Australia: Not manufactured locally; originator and sole manufacturer in Korea is Dong-A Pharmaceutical
• Registration Status In Australia: Not TGA-registered or PBS-listed as of July 2025
• OTC / Rx Classification: Prescription Only (Rx) in all registered countries

Latest Research Highlights

Patients want to know whether Zydena works and how safe it is compared with better-known drugs like Viagra or Cialis.

Most clinical evidence for udenafil comes from South Korean trials and regional post-marketing data supplied by the manufacturer.

Contemporary literature from 2022–2025 is limited to small open-label studies and observational series rather than large randomised controlled trials.

Reported onset is roughly 30–60 minutes with duration up to about 12 hours in these small studies.

Common adverse events match the PDE5 inhibitor class and include headache, flushing and nasal congestion.

No large Australian RCTs or public PBS/TGA randomised safety registries for udenafil were identified up to July 2025.

Comparative pharmacology places udenafil alongside sildenafil, tadalafil and vardenafil as an alternative PDE5 inhibitor with a moderate onset and extended duration versus sildenafil.

Data gaps include long‑term cardiovascular safety and robust head‑to‑head trials versus tadalafil in Australian populations.

Clinical Effectiveness In Australia

Patients often ask whether Zydena has local approval or safety monitoring here.

There is no public TGA registration or PBS listing for Zydena/udenafil up to July 2025.

Australian clinicians therefore rely on international post‑marketing data and class evidence when advising patients about udenafil.

Short‑term effectiveness signals from origin markets indicate improved erectile function and patient satisfaction similar to other PDE5 inhibitors.

Reported practical advantages include a moderate onset and longer duration than sildenafil, which some patients prefer.

The TGA would be the central channel for adverse event surveillance should imported or unregistered supplies produce reports.

As of July 2025 there is no published domestic safety signal for udenafil on TGA portals.

• Clinician Checklist: Confirm cardiovascular stability and absence of nitrate therapy before discussing udenafil.
• Clinician Checklist: Reconcile medications using My Health Record or PBS scripts to avoid interactions with CYP3A4 inhibitors.
• Clinician Checklist: Discuss lack of TGA approval and absence of PBS subsidy when counselling on costs and legal options.

TGA/PBS Status: Not TGA‑registered; not PBS‑listed as of July 2025.

Indications And Expanded Uses

People want clarity on what Zydena is approved to do and what clinicians might use it for off‑label.

Registered indication in origin markets is erectile dysfunction for on‑demand use.

Product information lists a standard initial dose of 100 mg taken 30–60 minutes before sexual activity.

The maximum single dose is 200 mg and dosing frequency should not exceed one dose per 24 hours.

Zydena is prescription‑only in registered countries.

Off‑label international uses reported in small series include investigational low‑dose daily regimens and adjunct use in pelvic‑floor rehabilitation, but these are not standard or widely approved.

In Australia, any off‑label prescribing requires informed consent, documentation of rationale and specialist input for complex cardiovascular or hepatic cases.

1. Labelled Use: Erectile dysfunction, on‑demand dosing.
2. On‑Label Dosing Parameters: Initial 100 mg; take 30–60 minutes prior; max 200 mg single dose; do not exceed one dose per 24 hours.
3. Off‑Label Considerations: Low‑dose daily regimens and niche rehabilitation roles should only be considered with specialist oversight.

Composition And Brand Landscape

Customers ask which brands exist and who makes them.

Active ingredient is udenafil (INN).

The originator and primary manufacturer is Dong‑A Pharmaceutical in Seoul, South Korea.

Common brand names are Zydena and alternate spellings like Zidena in CIS markets, and Udenafilo in some Latin markets and online sources.

As of July 2025 there are no approvals or branded packaging reported for the USA, Canada or EU.

Brand map for Australia: likely absence from TGA listings; available through online import channels rather than mainstream pharmacy shelves.

Contraindications And Special Precautions

People often worry about dangerous drug mixes and who should avoid utenafil entirely.

Absolute contraindications include hypersensitivity to udenafil and concurrent nitrate therapy because of risk of severe hypotension.

Severe hepatic or renal impairment and serious cardiovascular disorders (unstable angina, recent myocardial infarction or stroke, severe arrhythmia) are also absolute contraindications.

Relative contraindications that need close monitoring include penile anatomical deformities, conditions that increase priapism risk such as sickle cell disease, hypotension, uncontrolled hypertension, bleeding disorders and peptic ulcer disease.

Australian high‑risk considerations include older adults with polypharmacy, people in rural or remote areas with limited emergency access, and Aboriginal and Torres Strait Islander men who have higher cardiovascular comorbidity prevalence.

Daily‑life cautions include avoiding heavy alcohol before dosing and not driving if feeling dizzy after taking a dose.

• Absolute Contraindications: Hypersensitivity to udenafil; concurrent nitrates; severe hepatic or renal impairment; unstable cardiovascular disease.
• Relative Contraindications: Penile deformity; priapism risk; hypotension; bleeding disorders; peptic ulcer disease.

Storage And Overdose Advice: Store below 25°C in original packaging and seek urgent care for overdose signs such as severe hypotension or priapism.

Dosage Guidelines

Patients commonly ask what dose to start and when to increase it.

Standard regimen is an initial 100 mg oral dose taken 30–60 minutes before sexual activity.

Maximum single dose is 200 mg and dosing should not exceed one dose per 24 hours.

Udenafil is not indicated for children under 18 years.

For elderly patients begin at 100 mg and adjust according to tolerability and effect.

Mild to moderate renal impairment requires cautious dosing and starting low, while severe renal impairment is not recommended due to lack of data.

Mild hepatic impairment may be treated cautiously but moderate to severe hepatic impairment should be avoided.

1. Start Dose: 100 mg for most adults.
2. Reassess: Review efficacy and adverse effects after a few attempts; consider dose change only with clinical oversight.
3. Maximum Dose: 200 mg single dose; do not exceed one dose per 24 hours.

Before prescribing in Australia, clinicians should document baseline blood pressure, cardiovascular status and concurrent medications, notably nitrates and CYP3A4 inhibitors.

Interactions Overview

Interaction questions are common, especially about heart medicines and antifungals.

Concurrent nitrates are an absolute contraindication because combining them with udenafil can cause severe hypotension.

Alpha‑blockers can produce additive blood‑pressure lowering and need careful timing and monitoring.

Strong CYP3A4 inhibitors such as ritonavir or ketoconazole can raise udenafil plasma levels and increase side effects.

Moderate CYP3A4 inhibitors require dose review and increased vigilance.

Alcohol potentiates vasodilatory effects and increases the risk of dizziness and hypotension.

Grapefruit juice may affect metabolism and is best avoided around dosing.

Pharmacist Checklist: Always ask about nitrates, HIV protease inhibitors, systemic antifungals and heavy alcohol use before supplying or counselling.

Cultural Perceptions And Patient Habits

Many Australians are price conscious and prefer brands with clear supply chains and PBS support.

Stigma around erectile dysfunction persists for some men, but telehealth and online pharmacies have normalised discrete access.

Rural patients often use telehealth and imported medicines because of limited local specialist access.

Aboriginal and Torres Strait Islander men may favour culturally safe primary care settings and strong relationships with local pharmacists.

Major pharmacy chains are trusted for generics and practical advice, and patients commonly ask pharmacists about alternatives and importation risks.

Counselling that is brief, non‑judgemental and practical tends to work best for price‑sensitive consumers.

• Patient Insight: Many will compare onset and duration when choosing between sildenafil, tadalafil and udenafil.
• Patient Insight: Telehealth has increased requests for mail order or imported erectile dysfunction tablets.

Cost And Availability Note: Urban patients typically have immediate access to TGA‑approved sildenafil and tadalafil generics, while rural patients may rely more on telehealth and importing options.

Availability And Pricing Patterns

Readers want to know whether Zydena is sold in Australian pharmacies and how much it costs.

Zydena/udenafil is not TGA‑registered or PBS‑listed as of July 2025 and is therefore not typically stocked by mainstream Australian pharmacies.

Major chains instead stock TGA‑approved PDE5 inhibitors such as sildenafil and tadalafil, often as affordable generics under PBS subsidy where eligible.

Some consumers choose to source udenafil via international e‑pharmacies or personal import, but this carries regulatory and quality risks.

Telehealth providers in Australia usually prescribe licensed PDE5 inhibitors rather than unregistered udenafil.

In our online pharmacy, zydena is available without a prescription, with discreet delivery to Australia in 5-14 days.

Report any adverse events to the TGA to ensure appropriate pharmacovigilance.

Comparable Medicines And Preferences

People often ask how Zydena stacks up against Viagra and Cialis when choosing a medicine.

Choice in Australia often depends on PBS subsidy, onset/duration preferences, prior response and interaction profile with other medicines such as antiretrovirals or antifungals.

FAQ

Here are the common questions Australian patients ask about Zydena.

1. Is Zydena available in Australia?

   Not TGA‑registered or PBS‑listed as of July 2025; obtaining it normally requires importation or specialist pathways and carries regulatory and quality risks.

2. Can I get it on prescription via telehealth?

   Australian clinicians typically prescribe TGA‑approved PDE5 inhibitors; telehealth services usually recommend licensed alternatives rather than unregistered udenafil.

3. How safe is it compared with Viagra?

   Short‑term safety appears consistent with the PDE5 inhibitor class, namely headache and flushing; absence of large local trials limits direct safety comparisons.

4. What should I do for priapism or severe dizziness?

   Seek emergency care immediately and report the event to the TGA, noting the medicine source and batch if known.

Guidelines For Proper Use

Pharmacists need quick, practical steps to counsel patients safely about Zydena or alternatives.

• Verify Current Medications: Check for nitrates, antiretrovirals, systemic antifungals and other CYP3A4 modulators.
• Assess Cardiovascular Stability: Confirm no recent MI, unstable angina, stroke or severe arrhythmia.
• Advise Dosing: Start at 100 mg taken 30–60 minutes before activity; do not exceed 200 mg in 24 hours.
• Storage Advice: Store below 25°C in original packaging and protect from moisture and sunlight.
• Adverse Event Reporting: Document suspected events and report to the TGA; recommend urgent care for priapism lasting over 4 hours or syncope.

Telehealth Script Template: Reconcile My Health Record medications, confirm absence of nitrates, discuss TGA status and PBS alternatives, and offer local dispensing options for sildenafil or tadalafil where appropriate.

Cultural Safety: Use non‑stigmatising language, offer private follow‑up and adapt explanations for rural or Indigenous contexts with appropriate local supports.

Delivery Across Australia